BRPI0923654A2 - composto, uso de um composto, e , composição farmacêutica. - Google Patents

composto, uso de um composto, e , composição farmacêutica.

Info

Publication number
BRPI0923654A2
BRPI0923654A2 BRPI0923654-6A BRPI0923654A BRPI0923654A2 BR PI0923654 A2 BRPI0923654 A2 BR PI0923654A2 BR PI0923654 A BRPI0923654 A BR PI0923654A BR PI0923654 A2 BRPI0923654 A2 BR PI0923654A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
general formula
single bond
compounds
Prior art date
Application number
BRPI0923654-6A
Other languages
English (en)
Japanese (ja)
Inventor
Nakao Akira
Gotanda Kentoku
Aoki Kazumasa
Hirano Shimpei
Hiruma Yoshiharu
Shiiki Takeshi
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of BRPI0923654A2 publication Critical patent/BRPI0923654A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
BRPI0923654-6A 2008-12-24 2009-12-22 composto, uso de um composto, e , composição farmacêutica. BRPI0923654A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008327476 2008-12-24
JP2008-327476 2008-12-24
PCT/JP2009/071338 WO2010074088A1 (ja) 2008-12-24 2009-12-22 環状アミン化合物

Publications (1)

Publication Number Publication Date
BRPI0923654A2 true BRPI0923654A2 (pt) 2018-10-16

Family

ID=42287696

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923654-6A BRPI0923654A2 (pt) 2008-12-24 2009-12-22 composto, uso de um composto, e , composição farmacêutica.

Country Status (17)

Country Link
US (1) US8173631B2 (pt)
EP (1) EP2374794B1 (pt)
JP (1) JP5551614B2 (pt)
KR (1) KR20110096547A (pt)
CN (1) CN102307852B (pt)
AU (1) AU2009331252C1 (pt)
BR (1) BRPI0923654A2 (pt)
CA (1) CA2748249C (pt)
CO (1) CO6400135A2 (pt)
IL (1) IL213697A (pt)
MX (1) MX2011006655A (pt)
NZ (1) NZ593675A (pt)
RU (1) RU2478616C2 (pt)
SG (1) SG172140A1 (pt)
TW (1) TWI389886B (pt)
WO (1) WO2010074088A1 (pt)
ZA (1) ZA201104619B (pt)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
JP4713026B2 (ja) * 2000-08-11 2011-06-29 日本たばこ産業株式会社 カルシウム受容体拮抗薬
ATE411275T1 (de) 2000-08-11 2008-10-15 Japan Tobacco Inc Calciumrezeptor-antagonisten
DK1619180T3 (da) * 2003-04-23 2010-03-29 Japan Tobacco Inc CaSR-antagonist
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
EP1630157A4 (en) * 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
JP2007522148A (ja) 2004-02-06 2007-08-09 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
US8362274B2 (en) 2004-05-28 2013-01-29 Mitsubishi Tanabe Pharma Corporation Arylalkylamine compound and process for preparing the same
US7592362B2 (en) 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
EP2056817A1 (en) 2006-09-01 2009-05-13 Bayer HealthCare AG Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system
PE20090492A1 (es) 2007-07-18 2009-05-27 Novartis Ag Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3
SG172141A1 (en) * 2008-12-24 2011-07-28 Daiichi Sankyo Co Ltd Indanyl compounds
WO2010113860A1 (ja) * 2009-03-31 2010-10-07 第一三共株式会社 ビフェニル-環状アミン化合物

Also Published As

Publication number Publication date
IL213697A (en) 2014-05-28
TWI389886B (zh) 2013-03-21
SG172140A1 (en) 2011-07-28
KR20110096547A (ko) 2011-08-30
RU2011130928A (ru) 2013-01-27
ZA201104619B (en) 2012-03-28
CN102307852A (zh) 2012-01-04
MX2011006655A (es) 2011-07-29
EP2374794B1 (en) 2015-11-04
IL213697A0 (en) 2011-07-31
CN102307852B (zh) 2013-12-18
TW201028375A (en) 2010-08-01
RU2478616C2 (ru) 2013-04-10
CO6400135A2 (es) 2012-03-15
EP2374794A1 (en) 2011-10-12
WO2010074088A1 (ja) 2010-07-01
CA2748249A1 (en) 2010-07-01
AU2009331252C1 (en) 2013-08-15
NZ593675A (en) 2012-06-29
JP5551614B2 (ja) 2014-07-16
EP2374794A4 (en) 2013-07-17
AU2009331252A1 (en) 2011-07-21
US8173631B2 (en) 2012-05-08
CA2748249C (en) 2013-07-02
US20110319468A1 (en) 2011-12-29
JPWO2010074088A1 (ja) 2012-06-21
AU2009331252B2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2008108386A1 (ja) 医薬組成物
ATE493386T1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
EA201270540A1 (ru) Макроциклические ингибиторы интегразы
ATE483707T1 (de) 2-cyclopropylthiazolderivate
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
NO20064077L (no) Kemokinreseptorantagonister
TNSN08407A1 (en) Organic compounds
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
TW200604183A (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
WO2007084914A3 (en) Phenoxy-substituted pyrimidines as adenosine receptor antagonists
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
EP1642880A4 (en) PROTEIN INHIBITORS OF THE HSP90 FAMILY
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
ATE457302T1 (de) Aromatische etherderivate als thrombin-hemmer
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
NO20063662L (no) Benzimidazolderivater
EP1813270A4 (en) PROTEIN INHIBITORS OF THE HSP90 FAMILY
EA200700997A1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
WO2010131192A3 (en) Novel oxazolidinone derivatives and their use as orexin receptor antagonists

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.